JAMA:美国儿童及青少年处方药使用变化趋势(1999-2014)

2018-05-16 zhangfan MedSci原创

研究发现,美国青少年及儿童处方药使用率呈下降趋势,儿童及青少年中哮喘、多动症及避孕药具的使用增加,而抗生素、抗组胺和上呼吸道药物的使用率下降

近日研究人员就美国儿童和青少年处方药使用趋势变化进行了考察。

研究人员考察了1999-2014年间国家健康与营养调查(NHANES)数据库数据,收集0-19岁人群处方药使用趋势变化。研究的主要终点是过去30天任何处方药物使用数据、服用的2种或更多处方药数据、药物治疗类行数据。

总计收集了38277名儿童及青少年处方药数据,平均年龄10岁,女孩占49%。1999-2002年间,30天任何处方药使用率由24.6%下降至2011-14年间的21.9%,每2年间下降0.41%;但2种以上处方药联用率未出现线性下降的趋势(2011-2014年2种以上处方药连用率为8.5%)。2011-14年间,最常用的处方药种类为哮喘药物(6.1%)、抗生素(4.5%)、注意缺陷/多动障碍(ADHD,3.5%)、局部用药(如皮肤科药物,鼻类固醇,3.5%)以及抗组胺药(2.0%)。39个类别中,14个药物类别存在线性变化趋势,8个品种使用率上涨,包括哮喘、多动症药物和避孕药具;6个品种下降,包括抗生素、抗组胺药和上呼吸道联合用药。

研究发现,美国青少年及儿童处方药使用率呈下降趋势,儿童及青少年中哮喘、多动症及避孕药具的使用增加,而抗生素、抗组胺和上呼吸道药物的使用率下降。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=317496, encodeId=476331e496a9, content=知之为知之.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue May 22 10:30:16 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316055, encodeId=043f3160559a, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu May 17 17:14:38 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315673, encodeId=3c673156e3a2, content=可以进行参考参考, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Wed May 16 15:34:11 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315650, encodeId=f5d431565008, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed May 16 14:37:49 CST 2018, time=2018-05-16, status=1, ipAttribution=)]
    2018-05-22 易水河

    知之为知之.学习学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=317496, encodeId=476331e496a9, content=知之为知之.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue May 22 10:30:16 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316055, encodeId=043f3160559a, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu May 17 17:14:38 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315673, encodeId=3c673156e3a2, content=可以进行参考参考, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Wed May 16 15:34:11 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315650, encodeId=f5d431565008, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed May 16 14:37:49 CST 2018, time=2018-05-16, status=1, ipAttribution=)]
    2018-05-17 虈亣靌

    了解一下.谢谢分享!

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=317496, encodeId=476331e496a9, content=知之为知之.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue May 22 10:30:16 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316055, encodeId=043f3160559a, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu May 17 17:14:38 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315673, encodeId=3c673156e3a2, content=可以进行参考参考, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Wed May 16 15:34:11 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315650, encodeId=f5d431565008, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed May 16 14:37:49 CST 2018, time=2018-05-16, status=1, ipAttribution=)]
    2018-05-16 易水河

    可以进行参考参考

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=317496, encodeId=476331e496a9, content=知之为知之.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Tue May 22 10:30:16 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316055, encodeId=043f3160559a, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Thu May 17 17:14:38 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315673, encodeId=3c673156e3a2, content=可以进行参考参考, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Wed May 16 15:34:11 CST 2018, time=2018-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=315650, encodeId=f5d431565008, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Wed May 16 14:37:49 CST 2018, time=2018-05-16, status=1, ipAttribution=)]
    2018-05-16 131****1460

    学习了受益匪浅

    0

相关资讯

网售处方药被判「死刑」,网上展示也不行

针对药品网络销售监督管理办法,食药监总局在2017年11月14日就发布了第一轮征集意见稿,与之相比,此次发布的《办法》措辞更为严谨。其中,最受人关注的一点就是处方药的网售定调。

国家药品监督管理局发文:板蓝根泡腾片等18种药品由处方药转换为非处方药

5月8日,国家药品监督管理局发布《关于调整板蓝根泡腾片等19个品种管理类别的公告(2018年第16号)》。根据《处方药与非处方药分类管理办法(试行)》(国家药品监督管理局令第10号)的规定,经国家药品监督管理局组织论证和审定,板蓝根泡腾片等18种药品由处方药转换为非处方药;伤湿止痛膏已不符合目前乙类非处方药确定原则,由乙类非处方药转换为甲类非处方药。

布洛芬服用过量有严重副作用 专家建议列为处方药

美国研究表明,在服用布洛芬和其他非甾体抗炎药的情况下,一旦过量,会对人体产生严重副作用。

网上处方药代购将被7*24全天候监控,天猫、京东、论坛、贴吧、QQ、微信、微博全部在内!

天猫医药馆、京东医药馆、360好药、药房网商城、八百方等国内当下主要网上药品零售平台悉数在列。

刚刚,这个药不能随便卖了

2月5日,国家食品药品监督管理总局发布了《关于修订精乌胶囊等4个品种药品说明书的公告》,将精乌胶囊调出非处方药目录,按处方药管理,百乐眠胶囊由乙类非处方药调整为甲类非处方药,同时对上述2种药品及七宝美髯丸、心元胶囊的说明书进行修订。

这些行为要被罚,不能再卖处方药

国务院发文,探索开放院外处方,随后广东省食药监局提醒药店违规经营处方药将被取消经营处方药资格。政策的走向,你看懂了吗?